All In Biotech

NDA 212643 · Univ Of Ca San Fran

Gallium Ga 68 Gozetotide

Gallium Ga-68 Gozetotide · Intravenous · Radioactive Diagnostic Agent

Novel

Last checked: Nov 19, 2026Latest source record: Jun 16, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Dec 1, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

134

22 Phase 3, 24 recruiting

FAERS reports

204

144 serious, 20 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 2, 2026.

Gallium Ga 68 Gozeotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Gallium Ga 68 Gozetotide Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. ( 1 )

Mechanism: Gallium Ga 68 gozetotode binds to prostate-specific membrane antigen (PSMA). It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 (Ga 68) is a β+ emitting radionuclide that allows positron emission tomography (PET).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 1, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • GALLIUM GA 68 GOZETOTIDE · GALLIUM GA-68 GOZETOTIDE 0.5-5mCi/mL · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Gallium Ga-68 Gozetotide" as an intervention, any sponsor and status, largest first.

All 134 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hot flush36
  • erectile dysfunction27
  • fatigue15
  • death11
  • overdose9
  • pathological fracture9
  • aspartate aminotransferase increased8
  • asthenia8
  • rash8
  • cerebral amyloid angiopathy7
  • drug interaction7
  • muscular weakness7

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202210
20236
20247
2025129
202652

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Univ Of Ca San Fran

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.